When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .
Health-related quality of life after myocardial infarction, does choice of method make a difference?
Abstract Objectives . The aim of this study was to compare health-related quality of life ( HRQoL ) scores obtained from the instrument Short Form (SF)-36 through the so-called SF-6D utilities , and those obtained from 15D , in patients with ST-elevation myocardial infa rct ion ( STEMI ) , and to evaluate the consequences in estimation of quality adjusted life years ( QALYs ) . Design . This was a sub- study of the Norwegian District Treatment of STEMI , in which patients with STEMI treated with tenecteplase , were r and omized to early angioplasty or st and ard management ( n = 266 ) .  HRQoL data were collected at all visits ( 0 , 1 , 3 , 7 and 12 months ) . All patients with complete data were included ( n = 248 ) . Results . The score range was 0.33–1.0 for SF-6D and 0.49–1.0 for 15D  . Mean utility scores from 15D were higher and had different distribution compared to scores from SF-6D . Mean QALY for the whole group was higher using 15D than SF-6D ( 0.89 vs. 0.77 ) . The incremental number of QALYs with early angioplasty compared to st and ard treatment was 0.005 ( 95 % CI : − 0.018 to 0.028 ) using SF-6D , and 0.004 ( 95 % CI : − 0.010 to 0.018 ) using the 15D instrument . Conclusions . Choice of instrument may influence HRQoL scores , but not necessarily the gain in QALYs
When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .